Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group

Hematol Oncol. 2022 Oct;40(4):801-804. doi: 10.1002/hon.2986. Epub 2022 Mar 24.

Dennis A Eichenauer^{1

2}, Ina Bühnen^{1

2}, Annette Plütschow^{1

2}, Carsten Kobe^{2

3}, Markus Dietlein^{2

3}, Clemens-Martin Wendtner⁴, Sven Thorspecken⁴, Max S Topp⁵, Mareike Mauser⁵, Bastian von Tresckow^{2

6}, Michael Fuchs^{1

2}, Peter Borchmann^{1

2}, Andreas Engert^{1

2}

¹ First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.
² German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.
³ Department of Nuclear Medicine, University of Cologne, Cologne, Germany.
⁴ Department of Hematology, Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Munich, Germany.
⁵ Second Department of Internal Medicine, University Hospital Würzburg, Würzburg, Germany.
⁶ Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

No abstract available

Keywords: Btk; NLPHL; ibrutinib; relapse; salvage therapy.

Publication types